Physician profile
Marc A Abbate
NPI 1316911845
$21,406.92
in general payments reported to CMS, 2019-2025
42 companies · $3,742 in 2025
The $3,742 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,829 · 2020: $845 · 2021: $1,292 · 2022: $2,628 · 2023: $7,105 · 2024: $3,966 · 2025: $3,742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $3,024 · Education: $365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,424.00 |
| Consulting Fee | $3,024.00 |
| Education | $364.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $3,468.80 | 2019-2025 | |
| Abbvie INC. | $1,944.00 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,613.99 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $1,316.92 | 2019-2025 | Winlevi, Ilumya, Absorica Ld |
| Leo Pharma INC. | $1,066.38 | 2019-2025 | Adbry |
| Lilly USA, LLC | $996.90 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $939.85 | 2019-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $927.54 | 2022-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $880.83 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $872.56 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $845.92 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Novartis Pharmaceuticals Corporation | $811.33 | 2019-2025 | |
| Amgen INC. | $734.01 | 2019-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $694.62 | 2019-2025 | Jublia, Arazlo, Duobrii |
| Ucb, INC. | $555.10 | 2019-2025 | Bimzelx, Cimzia |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Abbate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.